Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 2025. december 31. [idézi 2026. április 14.];40(2):251-62. Elérhető: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001